WayPath is a development-stage companion animal pharmaceutical company formed in 2019 and led by two Louisiana State University (“LSU”) oncology researchers with over 50 years of combined experience.
WayPath has developed new and innovative anti-cancer metabolic compounds for companion animals and holds the exclusive license and commercialization rights from LSU for over 300 variants of our lead compound, PP1
6M new cancer diagnoses for canines each year
1 in 4 canines will be diagnosed with cancer
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.